PRCT Stock Summary and Trading Ideas (Procept Biorobotics | NASDAQ:PRCT)

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Procept Biorobotics trades on the NASDAQ stock market under the symbol PRCT.

As of December 29, 2025, PRCT stock price declined to $32.05 with 533,642 million shares trading.

PRCT has a beta of 0.84, meaning it tends to be less sensitive to market movements. PRCT has a correlation of 0.09 to the broad based SPY ETF.

PRCT has a market cap of $1.79 billion. This is considered a Small Cap stock.

Last quarter Procept Biorobotics reported $83 million in Revenue and -$.38 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.04.

In the last 3 years, PRCT traded as high as $103.81 and as low as $24.83.

The top ETF exchange traded funds that PRCT belongs to (by Net Assets): VTI, IWM, VB, VBK, BOTZ.

PRCT has underperformed the market in the last year with a price return of -61.6% while the SPY ETF gained +15.7%. PRCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.6% and -10.9%, respectively, while the SPY returned +4.3% and +1.2%, respectively.

PRCT support price is $31.04 and resistance is $33.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRCT shares will trade within this expected range on the day.